Physician profile

Andrew Warner

Emergency Medicine · Mobile, AL

NPI 1538522198

$169.70

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$19.44

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $28.71 2019
Inari Medical, INC. $19.44 2024 Ct Thrombectomy System Kit, Flowtriever Catheter, S
Astrazeneca Pharmaceuticals LP $18.50 2021
Pacira Pharmaceuticals Incorporated $18.47 2019
Csl Behring $17.88 2019
Janssen Pharmaceuticals, INC $17.33 2021
Novo Nordisk INC $13.89 2019
Chiesi USA, INC. $13.07 2021
E.R. Squibb & Sons, L.L.C. $11.32 2019
Genentech USA, INC. $11.09 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Andrew Warner

$169.70

in general payments reported 2019-2025

Years
2019-2024
Top company
Glaxosmithkline, LLC.

https://glasscript.com/doctor/2783960/andrew-warner

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.